Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | ANPEP | P15144 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23520330 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL14198796 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL15354479 | 0.82 | ALDH1A1 (0.72) | ALDH1A1 | |
| SCHEMBL13822102 | 0.82 | ALDH1A1 (0.72) | ALDH1A1 | |
| SCHEMBL8777100 | 0.82 | ALDH1A1 (0.72) | ALDH1A1 | |
| SCHEMBL5551895 | 0.82 | ALDH1A1 (0.85) | ALDH1A1 | |
| SCHEMBL5551897 | 0.82 | ALDH1A1 (0.85) | ALDH1A1 | |
| SCHEMBL17948650 | 0.82 | ALDH1A1 (0.85) | ALDH1A1 | |
| SCHEMBL14932683 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MMP2MMP9MMP8 | |
| SCHEMBL30493601 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | claimed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | claimed |
| WO-2010065709-A2 | HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | KHAN AMIN (US) | 2010-06-10 | — | — | WO | claimed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-112121171-A | Neuroactive compounds and methods of use thereof | 萨奇治疗股份有限公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3204011-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057713-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057713-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010065709-A2 | HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | KHAN AMIN (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | ALDH1A1 832/4885MMP2 133/4885MMP9 346/4885 |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | GLS, HGFAC, AADAC | ALDH1A1 832/4885MMP2 133/4885MMP9 346/4885 |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | ALDH1A1 1946/4885MMP2 4785/4885MMP9 4726/4885 |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | ALDH1A1 1946/4885MMP2 4785/4885MMP9 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.